MLICM
LXEO icon

Metropolitan Life Insurance Company (MetLife)’s Lexeo Therapeutics LXEO Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-599
Closed -$9.39K – 1213
2024
Q1 		$9.39K Buy
+599
New +$9.37K ﹤0.01% 2152

Other funds holding LXEO

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DCP
D1 Capital Partners New York $11.2B AUM 15.78% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s LXEO Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Lexeo Therapeutics (LXEO) in Q2 2024, closing a stake of 599 shares — an estimated $9.39K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in LXEO in Q1 2024 and held it in 1 quarter. The position peaked at $9.39K in Q1 2024. 59 funds tracked by Wall St. Rank hold LXEO as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Lexeo Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 599 Lexeo Therapeutics shares in Q2 2024, an estimated $9.39K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Lexeo Therapeutics in Q1 2024 and held it in 1 quarter.
  • Metropolitan Life Insurance Company (MetLife)'s Lexeo Therapeutics position peaked at $9.39K in Q1 2024.
  • 59 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.